Browse TPM4

Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Note=Associates with F-actin stress fibers.
Domain PF00261 Tropomyosin
Function

Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction. Smooth muscle contraction is regulated by interaction with caldesmon. In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments (By similarity). Binds calcium (PubMed:1836432).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0030048 actin filament-based movement
GO:0030049 muscle filament sliding
GO:0033275 actin-myosin filament sliding
GO:0070252 actin-mediated cell contraction
Molecular Function GO:0003779 actin binding
GO:0008307 structural constituent of muscle
Cellular Component GO:0001725 stress fiber
GO:0002102 podosome
GO:0005862 muscle thin filament tropomyosin
GO:0005865 striated muscle thin filament
GO:0005884 actin filament
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030055 cell-substrate junction
GO:0030863 cortical cytoskeleton
GO:0031941 filamentous actin
GO:0032432 actin filament bundle
GO:0036379 myofilament
GO:0042641 actomyosin
GO:0043292 contractile fiber
GO:0044448 cell cortex part
GO:0044449 contractile fiber part
GO:0097517 contractile actin filament bundle
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04260 Cardiac muscle contraction
hsa04261 Adrenergic signaling in cardiomyocytes
Reactome R-HSA-397014: Muscle contraction
R-HSA-445355: Smooth Muscle Contraction
R-HSA-390522: Striated Muscle Contraction
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TPM4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TPM4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TPM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6110.0388
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6960.844
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5420.826
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6890.0868
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4870.874
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9420.812
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1990.741
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4150.868
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.060.983
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3610.865
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4630.653
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1270.168
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TPM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TPM4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TPM4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TPM4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TPM4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TPM4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TPM4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTPM4
Nametropomyosin 4
Aliases HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TPM4 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TPM4.
ID Name Drug Type Targets #Targets
DB12695Phenethyl IsothiocyanateSmall MoleculeACTA2, ACTB, ATP5B, ATP5I, ATP5L, CYB5B, DIABLO, FBXO41, HNRNPF, H ......45